Life Sciences



Meet the Co-chairs - TAGLAW


Tauber, Paul J.
Coblentz, Patch, Duffy & Bass LLP
ptauber@coblentzlaw.com


Life Sciences


Kvale's Life Sciences Team has issued a new newsletter with important healthcare and life sciences updates in Norway. 

Included in the newsletter: 

  1. Branded vs. generic prescription
  2. The pediatric regulation will be implemented in Norwegian law as from 1 September 2017. The pharmaceutical industry can apply for a patent extension from 1 August.
  3. Medical Devices – The supervision of medical equipment will be transferred to the Norwegian Medicines Agency
  4. New maximum and minimum limits for Food Supplements

Click here to read the newsletter.


Contact: Rainer Herzig; Preslmayr Rechtsanwälte (Austria)

Introduction

Article 13(1) of the EU Supplementary Protection Certificate (SPC) Regulation (469/2009)(1) provides that an SPC will take effect at the end of the lawful term of a basic patent for a period equal to that which elapsed between the date on which the basic patent application was lodged and the date of the first authorisation to place the product on the market, reduced by five years. Article 13 neither clearly indicates whether the rule for calculating the period of exclusivity conferred by an SPC is governed by the procedural law of the member state concerned or solely by the provision nor whether the period counts from the date of adoption or the date of notification of the marketing authorisation. Although there is only a small timespan between these two dates, the economic impact of this difference is substantial.

Read more: ECJ rules on date of first authorisation